These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21293833)

  • 21. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
    Lenz HJ
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR as a target: rationale for therapy.
    Wujcik D
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
    Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
    Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common side effects of anti-EGFR therapy: acneform rash.
    Sipples R
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
    Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
    Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
    Eames T; Grabein B; Kroth J; Wollenberg A
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):958-60. PubMed ID: 20015177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
    Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
    J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption.
    Farahnik B; Kwong B; Murase J
    J Am Acad Dermatol; 2016 Nov; 75(5):e191. PubMed ID: 27745649
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
    Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
    Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
    Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
    Lee MW; Seo CW; Kim SW; Yang HJ; Lee HW; Choi JH; Moon KC; Koh JK
    Acta Derm Venereol; 2004; 84(1):23-6. PubMed ID: 15040473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions.
    Andrews ED; Garg N; Patel AB
    J Am Acad Dermatol; 2020 Apr; 82(4):998-1000. PubMed ID: 31604105
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
    Lee SL; Tan BS; Chan LC
    J Oncol Pharm Pract; 2013 Sep; 19(3):273-8. PubMed ID: 23161875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.
    Chen AP; Setser A; Anadkat MJ; Cotliar J; Olsen EA; Garden BC; Lacouture ME
    J Am Acad Dermatol; 2012 Nov; 67(5):1025-39. PubMed ID: 22502948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
    Bierbrier R; Lam M; Pehr K
    Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.